Dr. Kyle Denton joined the ALS Therapy Development Institute in 2016. He is currently working on establishing high-throughput methods for generating neural subtypes from patient-induced pluripotent stem cells to use in phenotype discovery and drug screening studies. Kyle joined the Institute because of his interest in neurodegenerative research and the opportunity to work with the resources that the Precision Medicine Program provides. He came to the Institute after a postdoctoral position in Dr. Jennifer Lippincott-Schwartz’s lab at the National Institutes of Health. Kyle received his Ph.D. from the University of Connecticut Health Center in Biomedical Sciences, with a concentration in neuroscience. Prior to that, he received his B.A. and M.A. from Clark University in Biochemistry and Molecular Biology in 2010 and 2011, respectively.
Current role